Nature Medicine, Published online: 05 October 2026; doi:10.1038/s41591-026-04713-y
Once-daily oral safiglipron is non-inferior to dapagliflozin for HbA1c reduction at all tested doses and superior at 90 mg, with greater improvements in glycemic control, similar modest weight loss and an acceptable safety profile in adults with type 2 diabetes.
